Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy
- 1 November 2011
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in European Journal of Gastroenterology & Hepatology
- Vol. 23 (12), 1150-1156
- https://doi.org/10.1097/meg.0b013e32834bb90a
Abstract
Hepatosplenic T-cell lymphoma (HSTCL) is a rare, lethal disease generally seen in young male patients with inflammatory bowel disease. The study of biologic and immunomodulator naive patients in Crohn's disease (SONIC), advocates combining infliximab with an immunomodulator in moderate-to-severe Crohn's disease. Unfortunately, combined immunosuppression increases risk for HSTCL. We herein review all cases of HSTCL reported to the Food and Drug Administration (FDA) in patients receiving TNF-α inhibitors. Individual reports from the FDA Adverse Event Reporting System database for lymphomas from the biological agents - infliximab, adalimumab, certolizumab, natalizumab, and etanercept were downloaded and analyzed with Microsoft Access. Full reports for all identified HSTCL cases were obtained from the FDA. Twenty-five cases of HSTCL were identified. Twenty-two (88%) patients had inflammatory bowel disease and three had rheumatoid arthritis. Four cases (16%) were in women and four patients were above 65 years of age. Twenty-four cases (96%) also received an immunomodulator (azathioprine, 6-mercaptopurine, or methotrexate). Two patients received adalimumab alone. HSTCL is no longer restricted to the previously identified risk group of young male patients, but can also occur in patients with rheumatoid arthritis, females and older adults receiving TNF-α inhibitors and immunomodulators. Improved disease outcomes using combination therapy should be tempered by the risk of developing HSTCL.Keywords
This publication has 19 references indexed in Scilit:
- A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2011
- Hepatosplenic T Cell Lymphoma Associated with Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease: UpdateJournal of Pediatric Gastroenterology and Nutrition, 2009
- Hepatosplenic T‐cell lymphoma following infliximab therapy for Crohn's diseaseThe Medical Journal of Australia, 2008
- Hepatosplenic T cell lymphoma in inflammatory bowel diseaseGut, 2008
- Hepatosplenic T Cell Lymphoma Associated With Infliximab Use in Young Patients Treated for Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2007
- Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapyLeukemia & Lymphoma, 2007
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis & Rheumatism, 2006
- Risk of haematopoietic cancer in patients with inflammatory bowel diseaseGut, 2005
- Hepatosplenic T-Cell Lymphoma in an Adolescent Patient after Immunomodulator and Biologic Therapy for Crohn DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2005
- Cancer risk in patients with inflammatory bowel diseaseCancer, 2001